IKBKG: A Promising Biomarker for Nanotechnology-Related Diseases
![Review Report on IKBKG Target / Biomarker](https://silexon.ai/img/target-biomarker-review.jpg?a=1)
![Content of Review Report on IKBKG Target / Biomarker](https://silexon.ai/img/target-biomarker-review-content.jpg?a=2)
IKBKG: A Promising Biomarker for Nanotechnology-Related Diseases
IKBKG, or inhibitor of nuclear factor kappa B kinase subunit gamma, is a protein that has been shown to have a variety of potential drug targets and may be a promising biomarker for certain diseases.
The nuclear factor kappa B (NFkB) signaling pathway is a well-established pathway that plays a role in regulating various cellular processes, including inflammation, DNA damage repair, and cell survival. The NFkB signaling pathway is activated by various factors, including stress, cytokines, and growth factors.
IKBKG is a protein that has been shown to inhibit the activity of the NFkB signaling pathway. Specifically, IKBKG has been shown to prevent NFkB from being activated by various stress and cytokine-induced signaling pathways. This means that when IKBKG is present, NFkB is unable to respond to stress and cytokine signals, which can have a negative impact on cellular processes and contribute to the development of various diseases.
IKBKG has been shown to have a variety of potential drug targets. For example, IKBKG has been shown to inhibit the activity of various NFkB-activated signaling pathways, including the production of pro-inflammatory cytokines and the regulation of cell survival. This suggests that IKBKG may be a useful drug target for diseases that are characterized by inflammation and cellular dysfunction.
IKBKG has also been shown to have a potential as a biomarker for certain diseases. For example, IKBKG has been shown to be reduced in the bloodstream of individuals with certain types of cancer, which suggests that it may be a useful biomarker for cancer. Additionally, IKBKG has been shown to be reduced in the bloodstream of individuals with inflammatory diseases, such as rheumatoid arthritis and asthma. This suggests that IKBKG may be a useful biomarker for these diseases.
In conclusion, IKBKG is a protein that has been shown to have a variety of potential drug targets and may be a promising biomarker for certain diseases. Further research is needed to fully understand the role of IKBKG in cellular processes and its potential as a drug target and biomarker.
Protein Name: Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma
Functions: Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor (PubMed:9751060, PubMed:14695475, PubMed:20724660). Its binding to scaffolding polyubiquitin plays a key role in IKK activation by multiple signaling receptor pathways (PubMed:16547522, PubMed:18287044, PubMed:19033441, PubMed:21606507, PubMed:27777308, PubMed:19185524, PubMed:33567255). Can recognize and bind both 'Lys-63'-linked and linear polyubiquitin upon cell stimulation, with a much higher affinity for linear polyubiquitin (PubMed:16547522, PubMed:18287044, PubMed:27777308, PubMed:19033441, PubMed:21606507, PubMed:19185524). Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3 (PubMed:19854139). Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination (PubMed:20724660)
The "IKBKG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IKBKG comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
IKZF1 | IKZF2 | IKZF3 | IKZF4 | IKZF5 | IL-1 Receptor | IL-10 Receptor | IL-11 receptor | IL-12 receptor | IL-13 receptor | IL-15 receptor | IL-17 Receptor | IL-2 receptor | IL-20 receptor | IL-22 Receptor | IL-23 receptor complex | IL-27 receptor | IL-3 receptor | IL-31 Receptor | IL-4 receptor | IL-5 receptor | IL-6 receptor | IL10 | IL10RA | IL10RB | IL10RB-DT | IL11 | IL11RA | IL12A | IL12A-AS1 | IL12B | IL12RB1 | IL12RB2 | IL13 | IL13RA1 | IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4